Latest Breaking News On - Paolof caimi - Page 1 : comparemela.com

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomNew jerseyMehdi hamadaniLoncastuximab tesirinePaolof caimiMohamed zakiParco cianiEugenia litzMary ann ondishKathryna logronioLausanne biopJohn wileyEuropean hematology associationExchange commission

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses

LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in

United statesCity ofUnited kingdomNew jerseyKathryna logronioPaolof caimiMehdi hamadaniParco cianiLausanne biopEugenia litzMary ann ondishLoncastuximab tesirineJohn wileyMohamed zakiEuropean hematology associationCollege of wisconsin

ADC Therapeutics Announces Updated LOTIS-2 Results

Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICML.

City ofUnited kingdomNew jerseyUnited statesLausanne biopMohamed zakiJohn wileyParco cianiMary ann ondishPaolof caimiEugenia litzLoncastuximab tesirineKathryna logronioMehdi hamadaniSons incEuropean commission

ADC Therapeutics SA: ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress

Poster presentation will highlight durable, long-term responses in relapsed/refractory DLBCL patients treated with ZYNLONTA ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2

United statesCity ofUnited kingdomNew jerseyEugenia litzAmanda loshbaughLausanne biopPaolof caimiMary ann ondishLoncastuximab tesirineMohamed zakiExchange commissionCompany annual report on formOverland pharmaceuticalsCompany on twitterDrug administration

ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress

Poster presentation will highlight durable, long-term responses in relapsed/refractory DLBCL patients treated with ZYNLONTA® . | May 11, 2023

New jerseyUnited statesCity ofUnited kingdomLausanne biopPaolof caimiMohamed zakiLoncastuximab tesirineCleveland clinic taussig cancer centerEuropean hematology associationCompany on twitterDrug administrationEuropean commissionChief medical officerTerm responsesUpdated results from